AC01

DRUG2 trials

Sponsors

AnaCardio AB

Conditions

Heart Failure With Reduced Ejection FractionHeart Failure With Reduced Ejection Fraction (HFrEF)

Phase 1

Phase Ib/IIa Trial With AC01 in Patients With HFrEF

CompletedNCT05642507

AnaCardio ABHeart Failure With Reduced Ejection Fraction

Start: 2023-02-23End: 2025-10-27Updated: 2026-05-07

Phase 2

A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure

Not yet recruitingNCT07584967

AnaCardio ABHeart Failure With Reduced Ejection Fraction (HFrEF)

Start: 2026-11-15End: 2028-08-30Target: 400Updated: 2026-09-14

Related Papers

Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study.

2026-06-24